ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Last update: yesterday, 11:24AM

297.10

2.12 (0.72%)

Previous Close 294.98
Volume 1,272,503
Price / Earnings (Forward) 18.12
Price / Sales 7.89
52 Weeks Range
190.75 (-35%) — 302.93 (1%)
TTM Dividend Yield 3.18%
Profit Margin 7.31%
Operating Margin (TTM) 30.43%
Diluted EPS (TTM) 2.35
Quarterly Revenue Growth (YOY) 8.40%
Quarterly Earnings Growth (YOY) -6.10%
Total Debt/Equity (MRQ) 4,789.60%
Current Ratio (MRQ) 0.760
Operating Cash Flow (TTM) 16.40 B
Levered Free Cash Flow (TTM) 16.94 B
Return on Assets (TTM) 8.34%
Return on Equity (TTM) 88.40%

AIStockmoo Score

-0.5
Value 35% -4.2
AI Insight info -4.2
Relative Valuation info NA
Financial Health info -0.7
Timing 35% 2.0
AI Technical info NA
Technical Oscillators info 4.0
Technical Moving Averages info -1.0
Smart Money 30% 0.8
Analyst Consensus info 0.0
Insider Activity info NA
News Mood info 2.9
Environment ×1.08
Macro Environment info -3.3
Sector vs Market (6M) +10.4%
Pillar Agreement ×0.86
Not in score
Price Volatility info -3.0
Final Score -0.48

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Bullish
Drug Manufacturers - General (Global) Mixed Bullish
Stock AbbVie Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ABBV - 3.18% - -
JNJ - 1.92% - 8.29
PFE - 6.00% - 1.85
NVO - 4.16% - 5.49
GSK - 3.66% - 4.14
BMY - 4.36% - 5.48

Select this tab to load the latest available analysis.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.10%
% Held by Institutions 74.87%

No data within this time range.

No data within this time range.

Date Type Details
12 Nov 2026 Yahoo Finance AbbVie (ABBV) Reports Positive Phase 3 QULIPTA Migraine Trial Results
AbbVie (NYSE:ABBV) reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention against topiramate. The TEMPLE study found QULIPTA achieved superior tolerability compared with topiramate in adults with migraine. QULIPTA also showed better efficacy than topiramate on key…
12 Nov 2026 Yahoo Finance Coca-Cola or AbbVie: The One Dividend Stock I’d Hold for the Next 20 Years
Key TakeawaysAbbVie raised its quarterly dividend 5. 2% to $1…
12 Nov 2026 Yahoo Finance The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira
NVDA, WMT and ABBV headline Zacks' latest research, with growth drivers and business risks shaping their investment outlooks.
12 Nov 2026 Yahoo Finance AbbVie Deal Altering The Investment Case For Nxera Pharma Stock (TSE:4565)?
Nxera Pharma announced in early November 2026 that its UK subsidiary entered an exclusive global license agreement with AbbVie for the EP4 agonist program in inflammatory bowel disease. The agreement includes a US$100 million upfront payment and potential milestones up to US$1.37 billion, plus…
11 Nov 2026 Yahoo Finance ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.
11 Nov 2026 Yahoo Finance Top Analyst Reports for NVIDIA, Walmart & AbbVie
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pioneer Bancorp, Inc. (PBFS) and Aspira Women's Health Inc. (AWHL).
11 Nov 2026 Yahoo Finance 3 Legacy Health Care Dividend Stocks That Never Go Out of Style
Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by a single cent.
10 Nov 2026 Yahoo Finance Can AbbVie (ABBV) Justify Its Valuation After Raised Guidance And Strong Results?
AbbVie (ABBV) just raised its full year 2026 revenue guidance to about US$67.8b and lifted its dividend, after reporting third quarter sales of US$17.4b and net income of US$4.2b. Recent price action has been strong, with AbbVie’s share price delivering a 6.1% 1 month gain and a 17.3% 3 month share…
TTM Dividend Yield 3.18%
5Y Average Dividend Yield 3.22%
Payout Ratio 268.80%
Ex Date Announcement Date Payment Date Details
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Cash
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Cash
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Cash
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Cash
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Cash
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Cash
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Cash
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Cash
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Cash
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Cash
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Cash
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Cash
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Cash
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Cash
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Cash
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Cash
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Cash
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Cash
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Cash
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Cash
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Cash
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Cash
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Cash
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Cash
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Cash
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Cash
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Cash
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Cash
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Cash
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Cash
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Cash
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Cash
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Cash
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Cash
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Cash
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Cash
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Cash
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Cash
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Cash
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Cash
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Cash
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Cash
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Cash
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Cash
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Cash
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Cash
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Cash
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Cash
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Cash
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 3.28 2 1.44
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Show more

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria